CURRENT REPORT 2/2021
January 7, 2021

Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

The Management Board of Ryvu Therapeutics S.A. ("Company") hereby announces that its Clinical Trial Application (CTA) to commence the First In Human (FIH), Phase I trial investigating SEL120 (RVU120), a selective CDK8/CDK19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HRMDS) has been fully approved by the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, and the respective Central Ethics Committee.

Following these approvals, the Company can expand the clinical trial already ongoing in the United States also in Poland, aiming to assess the safety and tolerability of SEL120 (RVU120) as well as to determine the Recommended Phase II Dose (RP2D) of the study drug, in participants with AML or HRMDS.

Legal basis: Article 17.1 of the Market Abuse Regulation

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board